GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ectin Research AB (XSAT:ECTIN B) » Definitions » Debt-to-EBITDA

Ectin Research AB (XSAT:ECTIN B) Debt-to-EBITDA : -0.08 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ectin Research AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ectin Research AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Ectin Research AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.76 Mil. Ectin Research AB's annualized EBITDA for the quarter that ended in Mar. 2024 was kr-9.15 Mil. Ectin Research AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.08.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Ectin Research AB's Debt-to-EBITDA or its related term are showing as below:

XSAT:ECTIN B' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.32   Med: -0.33   Max: -0.04
Current: -0.05

During the past 4 years, the highest Debt-to-EBITDA Ratio of Ectin Research AB was -0.04. The lowest was -1.32. And the median was -0.33.

XSAT:ECTIN B's Debt-to-EBITDA is ranked worse than
100% of 270 companies
in the Biotechnology industry
Industry Median: 1.31 vs XSAT:ECTIN B: -0.05

Ectin Research AB Debt-to-EBITDA Historical Data

The historical data trend for Ectin Research AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ectin Research AB Debt-to-EBITDA Chart

Ectin Research AB Annual Data
Trend Aug19 Aug20 Dec22 Dec23
Debt-to-EBITDA
-1.32 -0.61 -0.06 -0.04

Ectin Research AB Quarterly Data
Aug19 Aug20 Mar21 Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.14 -0.09 -0.02 -0.08

Competitive Comparison of Ectin Research AB's Debt-to-EBITDA

For the Biotechnology subindustry, Ectin Research AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ectin Research AB's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ectin Research AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ectin Research AB's Debt-to-EBITDA falls into.



Ectin Research AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ectin Research AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0.73) / -17.198
=-0.04

Ectin Research AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0.76) / -9.152
=-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Ectin Research AB  (XSAT:ECTIN B) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Ectin Research AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ectin Research AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ectin Research AB (XSAT:ECTIN B) Business Description

Traded in Other Exchanges
N/A
Address
Pepparedsleden 1, Molndal, SWE, 431 83
Ectin Research AB is a pharmaceutical company developing a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370 engages in the treatment of metastatic bladder cancer, and has also shown potential in other cancers such as breast, colorectal and prostate cancer cells.

Ectin Research AB (XSAT:ECTIN B) Headlines

No Headlines